This Is MS Multiple Sclerosis Community: Knowledge & Support

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

Bayhill Therapeutics, Inc. Research on Multiple Sclerosis Chosen as One of the Meeting's Scientific Program Highlights at the 58th Annual Meeting of the American Academy of Neurology4/4/2006 8:41:00 AM EST

Bayhill Therapeutics will make two presentations today at the 58th Annual Meeting of the American Academy of Neurology in San Diego in connection with development of the company's lead drug candidate, BHT-3009, for the treatment of multiple sclerosis.

NOTE: The S02.004 abstract has been selected by the AAN's
Scientific Program Subcommittee and the Science Committee as one
of the meeting's scientific program highlights (top 5 percent) for
inclusion in the "Scientific Program Highlights Plenary Session"
on Friday evening, April 7, from 5:15-6:15 PM. For more
information about this acknowledgement by the Scientific Program,
contact Kevin Heinz at kheinz@aan.com, or (651) 695-2773.

RESEARCH/PROGRAM HIGHLIGHTS

1. First in man trial of a DNA plasmid therapeutic for multiple
sclerosis (MS), an autoimmune disease.

2. BHT-3009 is an antigen-specific treatment for MS and has been
specifically designed to NOT cause broad-based
immunosuppression, or adverse events.

3. BHT-3009 expresses full-length human MBP, the major target of
the autoimmune response in the majority of MS patients.

4. Distinguished from other antigen-specific approaches attempted
in the clinic, the DNA allows low-level persistence of the
antigen for 2-4 weeks. BHT-3009 has been engineered to
tolerize the patient's immune system by targeting the entire
MBP (the protein that causes multiple sclerosis) molecule
rather than only a small portion of it.

Who is online

This site does not offer, or claim to offer, medical, legal, or professional advice.
All treatment decisions should always be made with the full knowledge of your physicians.
This is MS does not create, endorse, or republish any content.
All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.